The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand

Cancer immunity

Phillip Parente²  Kelly-Anne Masterman²  Michael Jefford²  Wendie Hopkins²  Eugene Maraskovsky²  Heather Jackson²  Nektaria Dimopoulos²  Jonathan Cebon²  Ian D. Davis²  Weisan Chen²  Dania Caron¹  Tsin Tai²  Mark Shackleton²  Qiyuan Chen² 

[1] Immunex/Amgen Corporation, Seattle, USAImmunex/Amgen Corporation, Seattle, USAImmunex/Amgen Corporation, Seattle, USA;Cancer Vaccine Laboratory, Ludwig Institute for Cancer Research, Austin Health, Studley Road, Heidelberg, 3084, AustraliaCancer Vaccine Laboratory, Ludwig Institute for Cancer Research, Austin Health, Studley Road, Heidelberg, 3084, AustraliaCancer Vaccine Laboratory, Ludwig Institute for Cancer Research, Austin Health, Studley Road, Heidelberg, 3084, Australia

关键词: clinical trial;    melanoma;    vaccination;    peptides;    imiquimod;    immunological monitoring;   

DOI  :  

学科分类：肿瘤学

来源: Cancer immunity

【 授权许可】

Unknown